Dimensional Fund Advisors LP Raises Holdings in Personalis, Inc. (NASDAQ:PSNL)

Dimensional Fund Advisors LP boosted its position in Personalis, Inc. (NASDAQ:PSNL - Free Report) by 144.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 410,083 shares of the company's stock after buying an additional 242,141 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.58% of Personalis worth $2,372,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in PSNL. abrdn plc acquired a new position in shares of Personalis during the 4th quarter worth approximately $1,722,000. Blue Water Life Science Advisors LP lifted its position in shares of Personalis by 13.3% during the 4th quarter. Blue Water Life Science Advisors LP now owns 1,132,900 shares of the company's stock valued at $6,548,000 after acquiring an additional 132,900 shares during the period. Jump Financial LLC bought a new stake in shares of Personalis during the 4th quarter worth $588,000. EntryPoint Capital LLC bought a new stake in shares of Personalis during the fourth quarter worth $275,000. Finally, Barclays PLC raised its position in Personalis by 67.1% in the fourth quarter. Barclays PLC now owns 109,368 shares of the company's stock valued at $632,000 after purchasing an additional 43,900 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company's stock.

Personalis Price Performance

PSNL traded down $0.01 during midday trading on Monday, reaching $4.94. 322,938 shares of the company's stock traded hands, compared to its average volume of 1,007,166. The firm has a fifty day moving average of $3.76 and a two-hundred day moving average of $4.45. The stock has a market capitalization of $436.59 million, a price-to-earnings ratio of -2.97 and a beta of 1.83. Personalis, Inc. has a 52 week low of $1.14 and a 52 week high of $7.20.

Personalis (NASDAQ:PSNL - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05. The firm had revenue of $20.61 million during the quarter, compared to analyst estimates of $17.41 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. Sell-side analysts forecast that Personalis, Inc. will post -1.4 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on PSNL shares. HC Wainwright raised their price objective on Personalis from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday, May 7th. Craig Hallum started coverage on Personalis in a report on Monday, March 17th. They set a "buy" rating and a $8.00 price target on the stock. Needham & Company LLC restated a "buy" rating and issued a $7.00 target price on shares of Personalis in a research note on Thursday, April 10th. Finally, Guggenheim started coverage on Personalis in a research note on Thursday. They issued a "buy" rating and a $6.00 target price on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Personalis currently has an average rating of "Buy" and an average price target of $7.67.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.